Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION phase 3 trial of lutetium Lu 177 vipivotide tetraxetan in progressive PSMA-positive metastatic castration-resistant prostate cancer
2018-000459-41Phase 3Unknown
- Sponsor
- Endocyte
- Start
- Jun 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Endocyte. Primary endpoints: radiographic progression-free survival and overall survival. Status: unknown.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-000459-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000459-41.